Geoff Birkett to Chair Fierce New Product Planning Summit 2025, Delivering Opening Remarks and Presenting Case Study on Launching Successful Brands.

Ensysce Biosciences' Geoff Birkett will chair the Fierce New Product Planning Summit 2025, focusing on informed, value-based, and data-driven decisions for commercial success. Birkett, a seasoned commercial strategy expert, will deliver opening remarks and present a case study on launching successful brands, including Ensysce's PF614 analgesic. The summit is the premier industry event for defining new product planning teams' functions.

Ensysce Biosciences, Inc. (NASDAQ: ENSC) has announced that Geoff Birkett, the company's Chief Commercial Officer, will chair the Fierce New Product Planning Summit 2025. The summit, scheduled for September 8-11, 2025, at the Pennsylvania Convention Center in Philadelphia, will focus on helping new product planning teams make informed, value-based, and data-driven decisions to ensure commercial success. Birkett will deliver opening remarks and present a case study on successful product launches, including Ensysce's PF614 analgesic.

Geoff Birkett brings extensive experience in product launches and commercial strategy. He has successfully brought to market several groundbreaking medicines in pain, addiction, and neuroscience. At Ensysce, he is currently leading the preparations for the launch of PF614, a first-in-class analgesic designed to combat severe pain while reducing abuse and overdose risks. Birkett's career spans leadership roles at Eli Lilly, Lundbeck, and AstraZeneca, where he launched several innovative medicines and oversaw the AZ merger process in ex-US markets, rising to the position of Global SVP for CNS and Oncology.

The Fierce New Product Planning Summit is the premier industry event for defining how new product planning teams and related functions make informed, value-based, data-driven decisions. Life science leaders convene annually to share insights on maximizing pipeline potential through disciplined strategy and execution.

Ensysce Biosciences is a clinical-stage company with a goal of disrupting the analgesic landscape by introducing a new class of highly novel opioids for the treatment of severe pain. The company leverages its Trypsin-Activated Abuse Protection (TAAPTM) and Multi-Pill Abuse Resistance (MPAR®) platforms to develop unique, tamper-proof treatment options for pain that minimize the risk of both drug abuse and overdose. Ensysce's pipeline is backed by a robust global intellectual property portfolio, offering hope to patients and providers confronting the challenges of pain management.

The summit will provide an opportunity for industry leaders to learn from Birkett's expertise and insights into the launch process and maximizing success. The event is designed to foster collaboration and innovation, helping participants make informed decisions that drive commercial success.

References:
[1] https://www.newswire.com/news/ensysce-biosciences-geoff-birkett-to-chair-the-fierce-new-product-planning
[2] https://www.stocktitan.net/news/ENSC/ensysce-biosciences-geoff-birkett-to-chair-the-fierce-new-product-w6hdlaobu38d.html